"Autolus had an exciting fourth quarter of 2022 with obe-cel reaching the primary endpoint of the pivotal FELIX study in an interim analysis and confirming its attractive safety profile in r/r adult ALL patients," said Dr. Christian Itin, Chief Executive Officer of Autolus. "Progress with obe-cel triggered two milestones from Blackstone totaling $70m and with the successful fundraise in December 2022, raising gross proceeds of $163.9m, we are well positioned to bring this innovative and potentially transformative treatment to an underserved ALL patient population. In 2023 we will be fully focused on submitting a BLA application at the end of the year and working towards commercial launch in 2024. We look forward to presenting data from all patients treated in the FELIX study at a medical conference in mid-2023."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AUTL:
- Autolus Therapeutics Reports Full Year 2022 Financial Results and Operational Progress
- Autolus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on March 7, 2023
- Biotech Alert: Searches spiking for these stocks today
- 2 “Strong Buy” Penny Stocks That Could Rally All the Way to $11 (or More)
- Autolus non-executive chairman John Johnson to not stand for re-election
